{"disease":{"id":"parkinson-disease-psychosis","name":"parkinson disease psychosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03152292","title":"The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study","phase":"","overall_status":"TERMINATED","enrollment_count":764,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04373317","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06068465","title":"A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Tasly Pharmaceutical Group Co., Ltd","has_results":false},{"nct_id":"NCT06388551","title":"A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT04592965","title":"Hallucinations in Parkinson's Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Olaf Blanke","has_results":false},{"nct_id":"NCT02969369","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT01518309","title":"An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT05240339","title":"Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)","phase":"","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06450184","title":"Bioequivalence Study of Pimavanserin 34 mg Capsule","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Humanis Saglık Anonim Sirketi","has_results":false},{"nct_id":"NCT03661125","title":"SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT04292223","title":"Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04579887","title":"Presence Hallucination in Parkinson's Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Olaf Blanke","has_results":false},{"nct_id":"NCT02762591","title":"Expanded Access of Pimavanserin for Patients With PD Psychosis","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}